期刊
ORAL ONCOLOGY
卷 52, 期 -, 页码 1-10出版社
ELSEVIER
DOI: 10.1016/j.oraloncology.2015.11.009
关键词
OX40; Oral cancer; Head and neck cancer; Immunotherapy; PD-1; CTLA-4
资金
- Oral and Maxillofacial Surgery Foundation Research Support Grant
- Chiles foundation
- Robert W. and Elsie Franz foundation
- Wes and Nancy Lematta foundation
- Lynn and Jack Loacker foundation
OX40 is a member of the tumor necrosis factor (TNF) receptor family and a potent co-stimulatory pathway that when triggered can enhance T-cell memory, proliferation and anti-tumor activity in patients with metastatic cancer. Ongoing investigations at our institution have demonstrated that OX40 expressing T cells are found in abundance in the tumors of patients with advanced stage head and neck squamous cell carcinoma (HNSCC). This has led to the initiation of human clinical trials investigating OX40-directed therapy for patients with HNSCC in both the metastatic and curative setting. The purpose of this review is to explore what is known about OX40 signaling and discuss how this pathway potentially can be modulated to improve outcome for patients with HNSCC. (C) 2015 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据